Denali Therapeutics, Inc. (DNLI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Denali Therapeutics, Inc. (DNLI)
Company Performance

Current Price

as of Oct 16, 2024

$27.66

P/E Ratio

N/A

Market Cap

$3.96B

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Metrics

Overview

  • HQSan Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerDNLI
  • Price$27.66+3.02%

Trading Information

  • Market Cap$3.96B
  • Float83.20%
  • Average Daily Volume (1m)814,443
  • Average Daily Volume (3m)922,315
  • EPS-$2.85

Company

  • Revenue$1.27M
  • Rev Growth (1yr)-100.00%
  • Net Income-$99.03M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$114.65M
  • EV$3.07B
  • EV/Revenue2,425.39
  • P/EN/A
  • P/S3,685.77
  • P/B2.85
Documents